LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.97
−0.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 1.5B | 1.5B | 1.3B | 935.1M |
| Cost of Revenue | 620.3M | 599.7M | 545.6M | 586.9M | 353.4M |
| Gross Profit | 936.0M | 942.0M | 988.3M | 709.5M | 581.7M |
| Operating Expenses | |||||
| R&D Expense | 173.1M | 177.3M | 168.1M | 77.7M | 311.7M |
| SG&A Expense | 460.6M | 453.8M | 371.6M | 267.2M | 233.8M |
| General & Admin Expense | 230.0M | 275.1M | 193.7M | 125.5M | 133.6M |
| Selling & Marketing Expense | 230.6M | 178.7M | 177.9M | 141.7M | 100.2M |
| Other Expenses | — | — | (8.4M) | — | — |
| Total Operating Expenses | 633.7M | 631.1M | 531.3M | 344.9M | 545.5M |
| Cost and Expenses | 1.3B | 1.2B | 1.1B | 931.8M | 898.9M |
| Operating Income (EBIT) | 302.3M | 310.8M | 457.0M | 364.6M | 36.2M |
| Non-Operating | |||||
| Interest Income | 11.7M | 23.4M | 36.8M | 19.6M | 2.6M |
| Interest Expense | 19.8M | 19.7M | 19.7M | 20.0M | 7.2M |
| Net Interest Income | (8.1M) | 3.6M | 17.2M | (381.0K) | (4.6M) |
| Other Non-Op Income/Expense | 60.6M | 3.0M | (26.0M) | 46.3M | (9.5M) |
| Non-Operating Income (excl Interest) | (80.4M) | (22.7M) | 6.3M | (66.3M) | 2.3M |
| EBT (Pre-Tax Income) | 363.0M | 313.8M | 431.0M | 410.9M | 26.7M |
| Income Tax Expense | 87.7M | 80.2M | 118.5M | 84.3M | (1.3M) |
| Bottom Line | |||||
| Net Income | 275.3M | 233.6M | 312.4M | 326.7M | 28.1M |
| Earnings from Cont. Ops | 275.3M | 233.6M | 312.4M | 326.7M | 28.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 275.3M | 233.6M | 312.4M | 326.7M | 28.1M |
| Per Share | |||||
| Basic EPS | $4.21 | $3.46 | $4.52 | $4.79 | $0.41 |
| Diluted EPS | $4.14 | $3.41 | $4.36 | $4.65 | $0.40 |
| Revenue Per Share | $23.88 | $22.84 | $22.17 | $18.99 | $13.65 |
| Shares | |||||
| Basic Shares Outstanding | 65.2M | 67.5M | 69.2M | 68.3M | 68.5M |
| Diluted Shares Outstanding | 67.5M | 68.4M | 71.7M | 70.2M | 70.7M |
| Profitability Metrics | |||||
| EBITDA | 465.4M | 403.6M | 515.3M | 491.0M | 81.8M |
| D&A | 82.6M | 70.1M | 64.6M | 60.0M | 47.9M |
| EBIT | 382.8M | 333.5M | 450.6M | 431.0M | 33.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026